Myovant will doubtless need the marketing muscle of its partner as it tries to dislodge AbbVie and Neurocrine Biosciences' rival drug Oriahnn (elagolix), which has already been on the US market ...
which made Astra realise that if it had continued with its SSRI drug development it would probably have beaten Lilly to this lucrative market. In 1990, the US Food and Drug Administration (FDA ...
American companies are investing more in their future and getting a better return on their investments than overseas peers, ...
A $1.8 trillion corner of the sustainable debt market is defying the wider downturn, as investors snap up bonds largely ...
Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights. The Dow Jones is currently trading at 42,576.03, a decline of 0.03 percent ...
Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights. The Dow Jones is currently trading at 42,770.77, up by 0.43 percent ...
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
The US recession and President Trump's aggressive trade policies are causing market instability. (Reuters ) The US markets are expected to trade in green this week but remain in a close range.
Holcim is sticking to its side of the bargain. The $62 billion Swiss building materials company on Tuesday released forecasts ...
Some drugmakers are taking the unusual step of sending more medicines by air to the U.S., two executives and two logistics ...
US stocks closed near session highs on Monday as investors welcomed reports that the next wave of President Trump's tariffs will be narrower than expected. On Monday afternoon, President Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback